Reliability and safety of minimally invasive esophagectomy after neoadjuvant chemoradiation: a retrospective study.

Publisher: BioMed Central Country of Publication: England NLM ID: 101265113 Publication Model: Electronic Cited Medium: Internet ISSN: 1749-8090 (Electronic) Linking ISSN: 17498090 NLM ISO Abbreviation: J Cardiothorac Surg

Original Publication: [London] : BioMed Central, 2006-

Carcinoma, Squamous Cell/*therapy ; Esophageal Neoplasms/*therapy; Aged ; Carcinoma, Squamous Cell/mortality ; Chemotherapy, Adjuvant ; China ; Combined Modality Therapy ; Esophageal Neoplasms/mortality ; Female ; Humans ; Male ; Middle Aged ; Minimally Invasive Surgical Procedures ; Neoadjuvant Therapy ; Patient Safety ; Postoperative Complications ; Reproducibility of Results ; Retrospective Studies ; Treatment Outcome

Background: Thoracic surgeons have recognized the advantages of minimally invasive esophagectomy (MIE). However, MIE for locally advanced esophageal cancer after neoadjuvant chemoradiotherapy (NCRT) is controversial. This study aimed to nvestigate and summarise the reliability and safety of MIE after NCRT.
Methods: We retrospectively analyzed the perioperative outcomes of patients with locally advanced esophageal cancer who underwent minimally invasive esophagectomy after neoadjuvant chemoradiotherapy from January 2016 to January 2018, and compared them with patients who underwent MIE alone during the same period.
Results: In total, 107 patients were eligible for the study. Forty-four patients underwent MIE after NCRT (CRM), and 63 patients underwent MIE alone (MA). The surgical duration (253.59 ± 47.51 vs. 222.86 ± 42.86 min), intraoperative blood loss (164.55 ± 109.09 vs. 146.19 ± 112.89 ml), number of lymph nodes resected (18.36 ± 8.01 vs. 22.10 ± 12.03), duration of the postoperative hospital stay (12.84 ± 6.57 vs. 14.60 ± 8.48 days), postoperative intubation time (5.68 ± 3.08 vs. 6.54 ± 4.97 days), total incidence of complications (34.10% vs. 31.7%), and R0 resection rate (95.45% vs. 96.83%) had no significant difference. The incidence of arrhythmia was higher in CRM (P < 0.02). No mortality occurred postoperatively within 30 days in either group.
Conclusion: Minimally invasive esophagectomy after neoadjuvant chemoradiotherapy is a feasible, safe, and beneficial for postoperative recovery of patients.

J Am Coll Surg. 2004 Jan;198(1):42-50. (PMID: 14698310)
Lancet Oncol. 2007 Mar;8(3):226-34. (PMID: 17329193)
Dis Esophagus. 2009;22(3):195-202. (PMID: 19191856)
Minerva Chir. 2009 Apr;64(2):121-33. (PMID: 19365313)
Minerva Chir. 2009 Apr;64(2):135-46. (PMID: 19365314)
Surg Endosc. 2010 Jul;24(7):1621-9. (PMID: 20108155)
Ann Thorac Surg. 2010 Apr;89(4):1319-26. (PMID: 20338377)
Lancet Oncol. 2011 Jul;12(7):681-92. (PMID: 21684205)
Ann Thorac Surg. 2011 Dec;92(6):2034-40. (PMID: 21945223)
J Gastrointest Surg. 2012 Mar;16(3):486-94. (PMID: 22183862)
Interact Cardiovasc Thorac Surg. 2012 Jun;14(6):725-8. (PMID: 22392934)
J Thorac Cardiovasc Surg. 2012 May;143(5):1125-9. (PMID: 22500593)
Lancet. 2012 May 19;379(9829):1887-92. (PMID: 22552194)
N Engl J Med. 2012 May 31;366(22):2074-84. (PMID: 22646630)
Arch Surg. 2012 Aug;147(8):768-76. (PMID: 22911078)
Surg Today. 2013 Mar;43(3):237-44. (PMID: 22926551)
Ann Thorac Surg. 2013 Jun;95(6):1930-7. (PMID: 23642437)
J Gastrointest Surg. 2013 Aug;17(8):1359-69. (PMID: 23715646)
Ann Surg Oncol. 2014 Feb;21(2):605-11. (PMID: 24100962)
Ann Thorac Surg. 2014 Feb;97(2):439-45. (PMID: 24266955)
J Laparoendosc Adv Surg Tech A. 2014 Oct;24(10):688-92. (PMID: 25180663)
Ann Thorac Surg. 2014 Nov;98(5):1880-5. (PMID: 25262396)
Gut. 2015 Mar;64(3):381-7. (PMID: 25320104)
J Thorac Cardiovasc Surg. 2015 Apr;149(4):1006-14; discussion 1014- 5.e4. (PMID: 25752374)
Dis Esophagus. 2016 Aug;29(6):583-8. (PMID: 25824527)
Lancet Oncol. 2015 Sep;16(9):1090-1098. (PMID: 26254683)
Ann Thorac Surg. 2016 Mar;101(3):1097-103. (PMID: 26652140)
World J Gastroenterol. 2015 Dec 7;21(45):12873-81. (PMID: 26668512)
World J Surg Oncol. 2016 Dec 8;14(1):304. (PMID: 27927246)
Lancet. 2017 Nov 25;390(10110):2383-2396. (PMID: 28648400)

Keywords: Esophageal squamous cell carcinoma (ESCC); Locally advanced esophageal cancer; Minimally invasive esophagectomy (MIE); Neoadjuvant chemoradiotherapy (NCRT)

Date Created: 20190530 Date Completed: 20190802 Latest Revision: 20200225

20231215

PMC6537410

10.1186/s13019-019-0920-0

31138245